CLS Newsletter, May 2016
CLS Newsletter, May 2016 is available on the company's website.
Lars-Erik Eriksson, CEO, Clinical Laserthermia Systems AB (publ)
Tel: +46 – (0)702 – 90 33 00 E-mail: email@example.com
Clinical Laserthermia Systems AB (publ) develops and markets a safe, gentle, effective, and clinically documented therapy for treatment of solid cancer tumors. The product is based on immunostimulating interstitial laser thermotherapy (imILT). CLS is listed on Aktietorget under the stock symbol CLS B. More information is available on the Company's website www.clinicallaser.se